Novartis touts surrogate endpoint win, nabs priority review for Fabhalta in IgAN

A Novartis drug with "pipeline in a pill" potential, according to one analyst group, has delivered on that promise once again.

Monday, Novartis said treatment with Fabhalta led to a "clinically meaningful and statistically significant" 38.3% reduction of proteinuria (protein in the urine) in patients with IgA nephropathy (IgAN). The result came from a pre-specified interim analysis of the phase 3 APPLAUSE-IgAN study.